Sarepta Therapeutics Inc to Discuss New Clinical Data and Integrated Analysis Call Transcript
Good afternoon, ladies and gentlemen, and welcome to Sarepta Therapeutics' SRP-9001 New Clinical Data and Integrated Analysis Conference Call. (Operator Instructions) As a reminder, today's program is being recorded.
At this time, I'll turn the call over to Doug Ingram, President and Chief Executive Officer. Please go ahead.
Thank you, Michelle, and thank you all for joining us today for a review of our most recent results regarding the functional benefits and safety of SRP-9001, our gene therapy.
After literally 1.5 decades of rational design, testing, optimization, brilliant preclinical evidence and then repeatedly confirming across multiple studies, SRP-9001 safety and efficacy profile, we, at Sarepta, have developed, as you can imagine, a significant conviction in the potential of SRP-9001 to change the trajectory of this disease, Duchenne. So you can also imagine how difficult it would be to exceed our expectations in the transformative potential of this
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |